Latigo Biotherapeutics, Inc.
LTGO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LTGO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LTGO
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing non-opioid pain medicines, with two product candidates in clinical development and one in preclinical development, and a limited operating history since its formation in November 2018 [sec · filed 2026-07-17].
Key risk: Going concern risk
Market Cap
$1.53B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 5 clinical trials for Latigo Biotherapeutics, Inc..
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing non-opioid pain medicines, with two product candidates in clinical development and one in preclinical development, and a limited operating history since its formation in November 2018 [sec · filed 2026-07-17].
- Latigo is a clinical-stage biopharmaceutical company focused on non-opioid pain medicines designed to stop pain transmission without addiction risk [sec · filed 2026-07-17].
- The company has two product candidates in clinical development (LTG-001 and LTG-321) and one in preclinical development (LTG-418) [sec · filed 2026-07-17].
- As of March 31, 2026, Latigo had $42.2 million in cash and cash equivalents and an accumulated deficit of approximately $266.1 million [sec · filed 2026-07-17].
- The company has no history of commercializing products and does not expect product revenues for a number of years, if ever [sec · filed 2026-07-17].
- Latigo expects to require substantial additional capital to fund its development programs and has a going concern risk if unable to raise such capital [sec · filed 2026-07-17].
What works
- Latigo is developing innovative non-opioid pain medicines that target a large and pervasive therapeutic market in the United States [sec · filed 2026-07-17].
- The company has three product candidates in its pipeline, with two already in clinical development, indicating progress in its research and development efforts [sec · filed 2026-07-17].
What to weigh
- Latigo has a limited operating history, no commercialized products, and has incurred significant losses, with an accumulated deficit of $266.1 million as of March 31, 2026 [sec · filed 2026-07-17].
- The company's independent registered public accounting firm has included a going concern explanatory paragraph, highlighting the risk of inability to continue as a going concern [sec · filed 2026-07-17].
- Latigo is substantially dependent on the success of its product candidates LTG-001 and LTG-321, which are still in clinical development and face significant regulatory and commercial risks [sec · filed 2026-07-17].
- The company will require substantial additional capital to fund its operations and development, and failure to obtain such capital could force it to delay or terminate its programs [sec · filed 2026-07-17].
From the filings
Quoted directly from source documents.
Latigo is a clinical-stage biopharmaceutical company developing non-opioid pain medicines.
“We are a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction.”
SEC filings · July 17, 2026
Latigo has two product candidates in clinical development and one in preclinical development.
“We are substantially dependent on the success of our product candidates, LTG-001 and LTG-321, which are in clinical development. We also have a product candidate in preclinical development, LTG-418.”
SEC filings · July 17, 2026
As of March 31, 2026, Latigo had $42.2 million in cash and cash equivalents.
“As of March 31, 2026, we had $42.2 million of”
SEC filings · July 17, 2026
Latigo has an accumulated deficit of approximately $266.1 million as of March 31, 2026.
“our accumulated deficit as of March 31, 2026 was approximately $266.1 million.”
SEC filings · July 17, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Independent auditor included a going concern paragraph; if unable to continue as a going concern, assets may be liquidated at lower values [sec · filed 2026-07-17].
- Dependence on few product candidates — Substantially dependent on LTG-001 and LTG-321 (clinical) and LTG-418 (preclinical); failure of any could materially harm business [sec · filed 2026-07-17].
- Need for substantial additional capital — Current cash insufficient to fund product candidates through approval; additional capital needed, and failure could delay or terminate programs [sec · filed 2026-07-17].
- No product revenue expected soon — Company does not expect product revenues for a number of years, if ever, and has no commercialization history [sec · filed 2026-07-17].
What to watch
- Progress of clinical trials for LTG-001 and LTG-321, including enrollment and results [sec · filed 2026-07-17].
- Ability to raise additional capital to fund operations and development beyond current cash runway [sec · filed 2026-07-17].
- Regulatory developments and interactions with the FDA for product candidates [sec · filed 2026-07-17].
- Preclinical advancement of LTG-418 and potential IND submissions [sec · filed 2026-07-17].
Sources: SEC filings · Generated August 28, 2026 · How we verify sources →
Run Latigo Biotherapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Latigo Biotherapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Latigo Biotherapeutics, Inc.?
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing non-opioid pain medicines, with two product candidates in clinical development and one in preclinical development, and a limited operating history since its formation in November 2018 [sec · filed 2026-07-17].
Who is the CEO of Latigo Biotherapeutics, Inc.?
Mr. Nima Farzan M.B.A. is the chief executive officer of Latigo Biotherapeutics, Inc. (LTGO).
Where is Latigo Biotherapeutics, Inc. headquartered?
Latigo Biotherapeutics, Inc. (LTGO) is headquartered in Thousand Oaks, CA, United States.
What therapeutic areas does Latigo Biotherapeutics, Inc. focus on?
Latigo Biotherapeutics, Inc. develops therapies across Oncology, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.